Skip to main content
Top
Published in: Dermatology and Therapy 4/2016

Open Access 01-12-2016 | Case Report

Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies

Authors: Jeremy Udkoff, Philip R. Cohen

Published in: Dermatology and Therapy | Issue 4/2016

Login to get access

Abstract

Scalp psoriasis with alopecia is a rare cutaneous reaction to tumor necrosis factor alpha antagonists. This reaction often reverses with discontinuation of the offending drug and initiation of topical treatments; however, irreversible hair loss may occur if a scarring alopecia develops. We describe a woman with Crohn’s disease who developed scalp psoriasis and alopecia secondary to infliximab. She had a remarkable recovery after discontinuation of infliximab and treatment with oral minocycline and topical therapy: mineral oil under occlusion, betamethasone lotion, and sequential coal tar, salicylic acid, and ketoconazole shampoos each day. The patient’s alopecia completely resolved within 4 months of initiating this treatment regimen. In summary, early diagnosis of alopecia secondary to tumor necrosis factor alpha antagonist therapy is crucial in preventing diffuse alopecia and scalp psoriasis. In addition to discontinuing the offending agent, initiating aggressive adjuvant treatment with an oral antibiotic, topical therapies, or both, should be considered to reverse tumor necrosis factor alpha antagonist-induced alopecia and/or scalp psoriasis.
Literature
1.
go back to reference Lee H-H, Song I-H, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester G-R, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486–91.CrossRefPubMed Lee H-H, Song I-H, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester G-R, Sterry W, Worm M. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol. 2007;156(3):486–91.CrossRefPubMed
2.
go back to reference Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–27.CrossRefPubMed Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11–12):1318–27.CrossRefPubMed
3.
go back to reference Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454–9.CrossRefPubMed Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454–9.CrossRefPubMed
4.
go back to reference El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010;16(2):182–3.CrossRefPubMed El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A. Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers. Inflamm Bowel Dis. 2010;16(2):182–3.CrossRefPubMed
5.
go back to reference Beccastrini E, Squatrito D, Emmi G, Fabbri P, Emmi L. Alopecia areata universalis during off-label treatment with infliximab in a patient with Behçet disease. Dermatol Online J. 2010;16(9):15.PubMed Beccastrini E, Squatrito D, Emmi G, Fabbri P, Emmi L. Alopecia areata universalis during off-label treatment with infliximab in a patient with Behçet disease. Dermatol Online J. 2010;16(9):15.PubMed
6.
go back to reference Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30(5):700–6. Joyau C, Veyrac G, Dixneuf V, Jolliet P. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30(5):700–6.
7.
go back to reference Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Van Assche G, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.CrossRefPubMed Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Van Assche G, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164(1):10–22.CrossRefPubMed
8.
go back to reference Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis. 2011;5(2):157–61.CrossRefPubMed Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohns Colitis. 2011;5(2):157–61.CrossRefPubMed
9.
go back to reference Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A, Armuzzi A. Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci. 2013;17(20):2831–6.PubMed Andrisani G, Marzo M, Celleno L, Guidi L, Papa A, Gasbarrini A, Armuzzi A. Development of psoriasis scalp with alopecia during treatment of Crohn’s disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci. 2013;17(20):2831–6.PubMed
10.
go back to reference Osório F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H, Azevedo F, Magina S. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225(2):163–7.CrossRefPubMed Osório F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H, Azevedo F, Magina S. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225(2):163–7.CrossRefPubMed
11.
go back to reference Ribeiro LBP, Rego JCG, Estrada BD, Bastos PR, Piñeiro Maceira JM, Sodré CT. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol. 2015;90(2):232–5.CrossRefPubMedPubMedCentral Ribeiro LBP, Rego JCG, Estrada BD, Bastos PR, Piñeiro Maceira JM, Sodré CT. Alopecia secondary to anti-tumor necrosis factor-alpha therapy. An Bras Dermatol. 2015;90(2):232–5.CrossRefPubMedPubMedCentral
12.
go back to reference Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, Péré P, Gautier S. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014;53(8):1465–9.CrossRef Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, Péré P, Gautier S. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014;53(8):1465–9.CrossRef
13.
go back to reference Tauber M, Buche S, Reygagne P, Berthelot J-M, Aubin F, Ghislain P-D, Cohen J-D, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M. Groupe de Recherche sur Psoriasis de Société Française de D, Club Rhumatismes et Inflammation (CRI), Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146–9.CrossRefPubMed Tauber M, Buche S, Reygagne P, Berthelot J-M, Aubin F, Ghislain P-D, Cohen J-D, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M. Groupe de Recherche sur Psoriasis de Société Française de D, Club Rhumatismes et Inflammation (CRI), Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146–9.CrossRefPubMed
14.
go back to reference Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50(1):25–32.CrossRefPubMed Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50(1):25–32.CrossRefPubMed
15.
go back to reference Mihaljević N, von den Driesch P. Successful use of infliximab in a patient with recalcitrant folliculitis decalvans. J Dtsch Dermatol Ges. 2012;10(8):589–90.PubMed Mihaljević N, von den Driesch P. Successful use of infliximab in a patient with recalcitrant folliculitis decalvans. J Dtsch Dermatol Ges. 2012;10(8):589–90.PubMed
16.
go back to reference Sillani C, Bin Z, Ying Z, Zeming C, Jian Y, Xingqi Z. Effective treatment of folliculitis decalvans using selected antimicrobial agents. Int J Trichology. 2010;2(1):20–3.CrossRefPubMedPubMedCentral Sillani C, Bin Z, Ying Z, Zeming C, Jian Y, Xingqi Z. Effective treatment of folliculitis decalvans using selected antimicrobial agents. Int J Trichology. 2010;2(1):20–3.CrossRefPubMedPubMedCentral
17.
go back to reference Loh TY, Cohen PR. Infliximab-associated psoriasiform dermatitis: case report and review of a seemingly paradoxical inflammatory response. Cureus. 2016;8(9):e773.PubMedPubMedCentral Loh TY, Cohen PR. Infliximab-associated psoriasiform dermatitis: case report and review of a seemingly paradoxical inflammatory response. Cureus. 2016;8(9):e773.PubMedPubMedCentral
18.
go back to reference Philpott MP, Sanders DA, Bowen J, Kealey T. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol. 1996;135(6):942–8.CrossRefPubMed Philpott MP, Sanders DA, Bowen J, Kealey T. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol. 1996;135(6):942–8.CrossRefPubMed
19.
go back to reference Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.CrossRefPubMed Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 2010;40(3):233–40.CrossRefPubMed
Metadata
Title
Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies
Authors
Jeremy Udkoff
Philip R. Cohen
Publication date
01-12-2016
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 4/2016
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-016-0156-z

Other articles of this Issue 4/2016

Dermatology and Therapy 4/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.